This was the stock's third consecutive day of gains.

As Bristol Myers Squibb rolls ahead with its plan to cut $1.5 billion in costs by the end of the year, the drugmaker is once ...

US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus ...

Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. | Bristol Myers Squibb is levering Fulcrum ...

Bristol Myers Squibb (BMY) concluded the recent trading session at $60.18, signifying a +0.6% move from its prior day's close.

Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...

We recently published a list of Jim Cramer’s Latest Portfolio: Top 10 Stocks to Watch. In this article, we are going to take ...

We recently published a list of 25 Best Dividend Stocks to Buy According to Billionaires. In this article, we are going to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...

Bristol-Myers Squibb (NYSE:BMY) recently declared a quarterly dividend of $0.62 per share on its common stock, reinforcing ...

Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult ...